drugset / Trial / NCT02240875

A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo

NCT02240875

Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to assess two new Ebola vaccines: cAd3-EBO Z at 3 different doses, and a second vaccine, MVA-BN® Filo, at 3 different doses. The study will enable us to assess the safety of the vaccines and the extent of the immune response in healthy volunteers. The investigators will do this by giving volunteers a either one or two vaccinations, doing blood and saliva tests and collecting information about any symptoms that occur after vaccination. This is the first trial to use either of these vaccines in humans. We plan to recruit a total of 92 volunteers to be vaccinated.

Timeline

Start
2014-09-17
Primary completion
2017-08-22
Completion
2017-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject MVA-BN-Filo Vaccine 4.4e+07 unknown
Subject MVA-BN-Filo Vaccine 2.2e+08 unknown
Subject MVA-BN-Filo Vaccine 4.4e+08 unknown
Subject cAd3-EBOZ Vaccine 1e+10 unknown Intramuscular
Subject cAd3-EBOZ Vaccine 2.5e+10 unknown Intramuscular
Subject cAd3-EBOZ Vaccine 5e+10 unknown Intramuscular